Менопаузальный синдром у женщин с cахарным диабетом

У женщин с нарушениями углеводного обмена выявляется иная структура проявлений климактерического синдрома, имеющая уникальные особенности. У пациенток с сахарным диабетом 1 типа менопауза наступает раньше ? в 46?48 лет.
Сахарный диабет не является противопоказанием для назначения заместительной гормональной терапии (ЗГТ). Выбор режима ЗГТ должен определяться индивидуально в каждом конкретном случае.

сахарный диабет, заместительная гормональная терапия, перименопауза, постменопауза

1. IDF "Diabetes atlas", 5th ed. Update, 2012.

2. Сахарный диабет: острые и хронические осложнения. Под редакцией академика РАН и РАМН И.И. Дедова, профессора М.В. Шестаковой. Москва: МИА; 2011. 480 с. [Diabetes mellitus: acute and chronic complications. Ed. by. Dedov II, Shestakova MV. Moscow: MIA; 2011. 480 p.] [Epub]

3. Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003 Mar;26(3):917-932. http://dx.doi.org/10.2337/diacare.26.3.917 [PubMed]

4. WHO Obesity and overweight. Fact sheet № 311, updated 2013. Geneva: WHO. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/

5. Шальнова СА, Деев АД. Масса тела у мужчин и женщин (результаты обследования российской, национальной, представительной выборки населения). Кардиоваскулярная терапия и профилактика. 2008; 7(6):60-63. [Shalnova SA, Deev AD. Body mass in men and women: the Russian national representative sample data. Cardiovascular Therapy and Prevention. 2008; 7(6):60-63.] [Epub]

6. Сметник ВП. Медицина климактерия. Москва: Литера; 2006. с 847. [Smetnik VP. Meditsina klimakteriya. Moscow: Litera; 2006. 847 p.]

7. Loutfly I, Abdel Aziz F, Dabbous NI, Hassan MHA. Women’s perception and experience of menopause: a community-based study in Alexandria, Egypt. Eastern Mediterranean Health Journal. 2006; 12 Suppl 2: S93-106. [PubMed]

8. Dorman JS, Steenkiste AR, Foley TP, Strotmeyer ES, Burke JP, Kuller LH, Kwoh CK Familial Autoimmune and Diabetes (FAD) Study. Menopause in type 1 diabetic women: is it premature? Diabetes. 2001;50(8):1857-1862. http://dx.doi.org/10.2337/diabetes.50.8.1857 [PubMed]

9. Sjöberg L, Pitkäniemi J, Haapala L, Kaaja R, Tuomilehto J. Menopause in women with type 1 diabetes. Diabetologia. 2013 Jan;56(1):78-81. http://dx.doi.org/10.1007/s00125-012-2731-x [PubMed]

10. Soto N, Iniguez G, Lopez P, Larenas G, Mujica V, Rey RA, et al. Anti-Mullerian hormone and inhibin B levels as markers of premature ovarian aging and transition to menopause in type 1 diabetes mellitus. Human Reproduction. 2009;24(11):2838-2844. DOI: http://dx.doi.org/10.1093/humrep/dep276 [PubMed]

11. Strotmeyer ES, Steenkiste AR, Foley TPJr, Berga SL, Dornam JS. Menstrual cycle differences between women with type 1 diabetes and women without diabetes. Diabetes Care. 2003;26(4):1016-1021. http://dx.doi.org/10.2337/diacare.26.4.1016 [PubMed]

12. Malacara JM, Huerta R, Rivera B, Esparza S, Fajardo ME. Menopause in normal and uncomplicated NIDDM women: physical and emotional symptoms and hormone profile. Maturitas. 1997;28(1):35-45. http://dx.doi.org/10.1016/S0378-5122(97)00051-0 [PubMed]

13. López-López R, Huerta R, Malacara JM. Age at menopause in women with type 2 diabetes mellitus. Menopause. 1999 Summer;6(2):174-178. [PubMed]

14. Григорян ОР, Анциферов МБ. Заместительная гормональная терапия у женщин, больных сахарным диабетом, в период пери- и постменопаузы. Руководство для врачей. Москва; 2001. С. 15-16. [Grigoryan OR, Antsiferov MB. Zamestitel'naya gormonal'naya terapiya u zhenshchin, bol'nykh sakharnym diabetom, v period peri- i postmenopauzy. Practical guidelines. Moscow; 2001. P. 15-16.]

15. Григорян ОР. Гормональная заместительная терапия и контрацепция у женщин, больных сахарным диабетом I и II типов в период перименопаузы: Автореф. дис. д-ра мед. наук. Москва; 2004. с. 18. [Grigoryan OR. Gormonal'naya zamestitel'naya terapiya i kontratseptsiya u zhenshchin, bol'nykh sakharnym diabetom I i II tipov v period perimenopauzy [Dissertation]. Moscow; 2004. p. 18.]

16. Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimen approved by the US Food and Drug Administration. Am J Med. 2005;118 Suppl 12B:64-73. http://dx.doi.org/10.1016/j.amjmed.2005.09.059 [PubMed]

17. de Villiers TJ, Gass ML, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M. Global Consensus Statement on menopausal hormone therapy. Maturitas. 2013;74(4):391-392. http://dx.doi.org/10.1016/j.maturitas.2013.02.001 [PubMed]

18. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8(5):538-554.http://dx.doi.org/10.1111/j.1463-1326.2005.00545.x [PubMed]

19. Mackay L, Kilbride L, Adamson KA, Chisholm J. Hormone replacement therapy for women with type 1 diabetes mellitus. Cochrane Database Syst Rev. 2013;6:CD008613. http://dx.doi.org/10.1002/14651858.CD008613.pub2 [PubMed]

20. Ferrara A, Karter AJ, Ackerson LM, Liu JY, Selby JV; Northern California Kaiser Permanente Diabetes Registry. Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: the Northern California Kaiser Permanente Diabetes Registry. Diabetes Care. 2001;24(7):1144-1150. http://dx.doi.org/10.2337/diacare.24.7.1144 [PubMed]

21. Matute ML, Kalkhoff RK. Sex Steroid Influence on Hepatic Gluconeogenesis and Glycogen Formation. Endocrinology. 1973;92(3):762-768. DOI: http://dx.doi.org/10.1210/endo-92-3-762 [PubMed]

22. Szekacs B, Vajo Z, Varbiro S, Kakucs R, Vaslaki L, Acs N, Mucsi I, Brinton EA. Postmenopausal hormone replacement improves proteinuria and impaired creatinine clearance in type 2 diabetes mellitus and hypertension. BJOG. 2000;107(8):1017-1021. http://dx.doi.org/10.1111/j.1471-0528.2000.tb10406.x [PubMed]

23. Howard BV, Hsia J, Ouyang P, Van Voorhees L, Lindsay J, Silverman A, et al. Postmenopausalhormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance. Circulation 2004;110:201-206. http://dx.doi.org/10.1161/01.CIR.0000134955.93951.D5 [PubMed]

24. Khoo CL, Perera M. Diabetes and the menopause. J Br Menopause Soc. 2005 Mar;11(1):6-11. http://dx.doi.org/10.1258/1362180053654475 [PubMed]

25. Lamon-Fava S, Herrington DM, Horvath KV, Schaefer EJ, Asztalos BF. Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status. Metabolism. 2010;59(12):1794-800. http://dx.doi.org/10.1016/j.metabol.2010.05.012 [PubMed]

26. Friday KE, Dong C, Fontenot RU. Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2001;86(1):48-52. http://dx.doi.org/10.1210/jc.86.1.48 [PubMed]

27. Brussaard HE, Gevers Leuven JA, Froelich M, Kluft C, Krans HM. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia. 1997 Jul;40(7):843-849. http://dx.doi.org/10.1007/s001250050758 [PubMed]

28. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, Emanuele NV, Levin SR, Pacold I, Lee HS. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Arch Intern Med. 1997;157(2):181-188. http://dx.doi.org/10.1001/archinte.1997.00440230053007 [PubMed]

29. Masding MG, Stears AJ, Burdge GC, Wootton SA, Sandeman DD. The benefits of oestrogens on postprandial lipid metabolism are lost in post-menopausal women with Type 2 diabetes. Diabet Med. 2006; 23(7):768-774. http://dx.doi.org/10.1111/j.1464-5491.2006.01867.x [PubMed]

30. Samaras K, Hayward CS, Sullivan D, Kelly RP, Campbell LV. Effects of post¬menopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study. Diabetes Care. 1999;22(9):1401-1407. http://dx.doi.org/10.2337/diacare.22.9.1401 [PubMed]

31. Григорян ОР, Андреева ЕН. Менопаузальный метаболический синдром (клиника, диагностика, лечение). Научно-практическое руководство. Москва; 2007. с. 61. [Grigoryan OR, Andreeva EN. Menopauzal'nyy metabolicheskiy sindrom (klinika, diagnostika, lechenie). Nauchno-prakticheskoe rukovodstvo. Moscow; 2007. p. 61.]

32. Kim C, Seidel KW, Begier EA, Kwok YS. Diabetes and depot medroxyprogesterone contraception in Navajo women. Arch Intern Med. 2001;161(14):1766-1771. http://dx.doi.org/10.1001/archinte.161.14.1766 [PubMed]

33. Sites CK, L’Hommedieu GD, Toth MJ, Brochu M, Cooper BC, Fairhurst PA. The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensivity in menopausal women: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2005;90(5):2701-2707. http://dx.doi.org/10.1210/jc.2004-1479 [PubMed]

34. De Cleyn K, Buytaert P, Coppens M. Carbohydrate metabolism during hormonal substitution therapy. Maturitas. 1989;11(3):235-242. http://dx.doi.org/10.1016/0378-5122(89)90216-8 [PubMed]

35. Crook D, Godsland I, Hull J, Stevenson JC. Hormone replacement therapy with dydrogesterone and 17β-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 months follow up. Br J Obstet Gynaecol. 1997;104(3):298-304. [PubMed]

36. Archer D, Thorneycroft I, Foegh M, Hanes V, Glant MD, Bitterman P, Kempson RL. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 12(6):716-727. http://dx.doi.org/10.1097/01.gme.0000177318.24005.b1 [PubMed]

37. Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids. 2003;68(10-13):891-905. http://dx.doi.org/10.1016/j.steroids.2003.08.008 [PubMed]

38. Carranza-Lira S. Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review. Clin Interv Aging. 2009;4:59-62. http://dx.doi.org/10.2147/CIA.S4117 [PubMed]

39. Григорян ОР, Андреева ЕН. Использование препарата «Анжелик» у женщин с сахарным диабетом 2 типа и артериальной гипертензией в период постменопаузы. Проблемы репродукции. 2007;13(3):52-55. [Grigorian OR, Andreeva E.N. Ispol'zovanie preparata «Anzhelik» u zhenshchin s sakharnym diabetom 2 tipa i arterial'noy gipertenziey v period postmenopauzy. Problemy reproduktsii. 2007;13(3):52-55.] [Epub]